May 7, 2019 5:30 am EDT Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
Apr 24, 2019 5:30 am EDT Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
Apr 3, 2019 5:30 am EDT Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
Apr 2, 2019 5:30 am EDT Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
Mar 18, 2019 5:30 am EDT Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
Mar 14, 2019 4:05 pm EDT Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
Mar 5, 2019 5:30 am EST Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
Feb 22, 2019 5:30 am EST Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
Feb 20, 2019 5:30 am EST Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation